Erasca Inc. (NASDAQ: ERAS)
$2.5800
+0.0100 ( +3.61% ) 1.0M
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Market Data
Open
$2.5800
Previous close
$2.5700
Volume
1.0M
Market cap
$726.61M
Day range
$2.4600 - $2.5990
52 week range
$1.6400 - $3.4500
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 63 | May 16, 2024 |
8-k | 8K-related | 12 | May 08, 2024 |
10-q | Quarterly Reports | 72 | May 08, 2024 |
ars | Annual reports | 1 | Apr 26, 2024 |
def | Proxies and info statements | 9 | Apr 26, 2024 |
8-k | 8K-related | 15 | Mar 28, 2024 |
10-k | Annual reports | 122 | Mar 27, 2024 |
8-k | 8K-related | 12 | Mar 27, 2024 |
4 | Insider transactions | 1 | Feb 07, 2024 |
4 | Insider transactions | 1 | Feb 07, 2024 |